{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:57:00Z","timestamp":1794315420196,"version":"4.9.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.semarthrit.2026.153025","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:44:19Z","timestamp":1781851459000},"page":"153025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy and safety of JAK inhibitors in Beh\u00e7et syndrome: systematic literature review"],"prefix":"10.1016","volume":"80","author":[{"given":"Bercemhan","family":"Sulu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-7305","authenticated-orcid":false,"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Kurtulus-Erozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10431","key":"10.1016\/j.semarthrit.2026.153025_bib0001","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et's syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/JMDH.S93681","article-title":"Beh\u00e7et's syndrome: providing integrated care","volume":"10","author":"Esatoglu","year":"2017","journal-title":"J Multidiscip Heal"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/BOR.0000000000000231","article-title":"Management of Beh\u00e7et's syndrome","volume":"28","author":"Ozguler","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153025_bib0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in patients with Beh\u00e7et's Disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153025_bib0006","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","article-title":"Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases","volume":"52","author":"Diamantopoulos","year":"2013","journal-title":"Rheumatol (Oxf)"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153025_bib0007","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Beh\u00e7et's syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatol (Oxf)"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153025_bib0008","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-023-01124-7","article-title":"Disease and treatment-specific complications of Beh\u00e7et syndrome","volume":"26","author":"Esatoglu","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"20","key":"10.1016\/j.semarthrit.2026.153025_bib0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for oral ulcers in Beh\u00e7et's syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.semarthrit.2026.153025_bib0011","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome\u2013a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0012","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/rheumatology\/keae416","article-title":"De novo manifestations during adalimumab treatment in Beh\u00e7et's syndrome","volume":"64","author":"Esatoglu","year":"2025","journal-title":"Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153025_bib0013","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/rheumatology\/keab944","article-title":"Emergence of new manifestations during infliximab treatment in Beh\u00e7et's syndrome","volume":"61","author":"Tukek","year":"2022","journal-title":"Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153025_bib0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0016","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et's syndrome","volume":"14","author":"Zou JC","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153025_bib0017","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Behcet's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153025_bib0018","first-page":"e1","article-title":"Use of Upadacitinib in refractory Behcet's disease: case report and systematic literature review","volume":"24","author":"Patel","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109298","article-title":"Baricitinib for the treatment of refractory vascular Behcet's disease","volume":"250","author":"Wang","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0020","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with Upadacitinib in two patients with anti-TNF-refractory macular edema associated with Beh\u00e7et's uveitis","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0021","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153025_bib0022","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","article-title":"Beh\u00e7et's disease: evaluation of a new instrument to measure clinical activity","volume":"38","author":"Bhakta","year":"1999","journal-title":"Rheumatol (Oxf)"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153025_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ibd.21313","article-title":"Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et's disease","volume":"17","author":"Cheon","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Behcet's disease: a pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153025_bib0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"8697","key":"10.1016\/j.semarthrit.2026.153025_bib0026","first-page":"1078","article-title":"International study group for Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153025_bib0027","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7651","key":"10.1016\/j.semarthrit.2026.153025_bib0028","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0029","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219810","article-title":"Correspondence on 'A pilot study of tofacitinib for refractory Behcet's syndrome'","volume":"82","author":"Zou","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153025_bib0031","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/MS9.0000000000000546","article-title":"Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal","volume":"85","author":"Sharma","year":"2023","journal-title":"Ann Med Surg (L)"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1242","article-title":"Coexistence of ankylosing spondylitis and Behcet's disease: successful treatment with upadacitinib","volume":"12","author":"Kraev","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"15","key":"10.1016\/j.semarthrit.2026.153025_bib0033","article-title":"Extended-release tofacitinib for refractory Beh\u00e7et disease: a case report","volume":"101","author":"Wang CRW","year":"2022","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0034","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s11739-025-03874-x","article-title":"Targeting Janus kinase 1 in refractory Beh\u00e7et's disease: a case report on the clinical efficacy of upadacitinib","volume":"20","author":"Ammoscato","year":"2025","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0035","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000002213","article-title":"Therapeutic potential of Janus kinase inhibitors for treating refractory beh\u00e7et disease","volume":"31","author":"Taniguchi","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0036","article-title":"Case report: refractory intestinal Beh\u00e7et's syndrome successfully treated with tofacitinib: a report of four cases","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483993","article-title":"Case report: successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behcet's disease","volume":"15","author":"Sha","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0038","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jgh.15997","article-title":"Gastrointestinal: refractory parastomal ulcers of Behcet's disease responsive to tofacitinib","volume":"38","author":"Lin","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153025_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15275","article-title":"Case report: peristomal pyoderma gangrenosum complicated by rheumatoid arthritis and Beh\u00e7et's disease successfully treated with baricitinib","volume":"27","author":"Ito","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"Supplement_1","key":"10.1016\/j.semarthrit.2026.153025_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0780","article-title":"P0606 The efficacy of upadacitinib in Intestinal Beh\u00e7et\u2019s Disease refractory to anti-TNF-\u03b1 therapy in a retrospective study","volume":"19","author":"Lu","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients","volume":"58","author":"Barroso-Garc\u00eda","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153025_bib0042","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et's phenotype: a multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8647","key":"10.1016\/j.semarthrit.2026.153025_bib0043","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"333","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"4 Suppl 50","key":"10.1016\/j.semarthrit.2026.153025_bib0044","first-page":"S84","article-title":"Cyclosporine for Beh\u00e7et's uveitis: is it associated with an increased risk of neurological involvement?","volume":"26","author":"Akman-Demir","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0046","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fmed.2021.713052","article-title":"Pathogenesis of Beh\u00e7et's Syndrome: genetic, environmental and immunological factors","volume":"8","author":"Mattioli","year":"2021","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153025_bib0047","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"10341","key":"10.1016\/j.semarthrit.2026.153025_bib0048","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.semarthrit.2026.153025_bib0049","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153025_bib0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Beh\u00e7et's syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0052","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm10112318","article-title":"Old and new challenges in Uveitis associated with Beh\u00e7et's disease","volume":"10","author":"Gueudry","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2026.153025_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1629886","article-title":"Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0054","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006503","article-title":"Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry","volume":"12","author":"Sonomoto","year":"2026","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153025_bib0055","first-page":"2057","article-title":"Tocilizumab may not be a good option for vascular involvement due to Beh\u00e7et's syndrome","volume":"42","author":"Ozdede","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0056","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","article-title":"Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u05f3s disease","volume":"46","author":"Emmi","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153025_bib0057","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omz041","article-title":"Secukinumab induced Beh\u00e7et's syndrome: a report of two cases","volume":"2019","author":"Dincses","year":"2019","journal-title":"Oxf Med Case Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153025_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2007.09.009","article-title":"Atherosclerosis in Beh\u00e7et's syndrome","volume":"38","author":"Seyahi","year":"2008","journal-title":"Semin Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:01:54Z","timestamp":1788753714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0049017226001150"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153025","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of JAK inhibitors in Beh\u00e7et syndrome: systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153025"}}